EN DE
Watch Dyadic International Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dyadic International Inc (DYAI) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Dyadic International Inc stock $0.28, price $0.37, that is 24.5% below the price, quality 22 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

DI Dyadic International Inc logo Thin data Nov 10, 2026

Dyadic International Inc

DYAI · US
Expensive, weak quality

Our calculation puts a fair price 24% below what the stock costs today.

Negative equity (buybacks among others)
Mixed vs. peers (2/5)
Fair value $0.2794 · Overvalued
Quality 22/100
Weak Growth (revenue 5y −5.1 %/yr in USD)
Negative free cash flow
Narrow moat 23/100
Thin data
Estimate
Watch Dyadic International Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6.49 $0.3400 Fair Value $0.2794 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.3400 – $6.49 · fair‑value band $0.2096 – $0.3493 · the $0.3700 price screens above the $0.2794 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Dyadic International in your weekly email

Every Wednesday you see whether Dyadic International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.

Show moreShow less

The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.

It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses.

Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Stock analysis

Dyadic International Inc (DYAI) currently trades at $0.3700, while our estimate is $0.2794, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.2096 (bear) to $0.3493 (bull), the price of $0.3700 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Dyadic International Inc reported revenue of $1.2M in FY2025 versus $2.4M in FY2021, a compound −15.4%/yr. Reported net income was −$7.4M in FY2025.

Key figures

Market cap $13.5M Micro · P/S ratio 3.58 · EPS (TTM) $−0.2300 · Return on equity −2,827% · Return on assets (EBIT) −74.9% (5-year average) · Operating margin −213% · Revenue growth (YoY) −0.6% · Free cash flow −$5.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 75% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −24%, DYAI screens richer than that median.

Fair Value

Bear $0.2096 Fair Value $0.2794 Bull $0.3493
Price $0.3700 · Downside -24.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 26
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 28
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleFrancisco Trust under agreement dated February 28, 199610% owner95,392 shares at $1.31$124,915Jul 24, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−64.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.1%
Start year 2020 (pandemic). Over 10 years: +14.6% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−625.9% (2020) → −579.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DYAI screens overvalued: fair value 24% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Dyadic International Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −24.5% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −74.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −0.6% · Below median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 3.55× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs DYAI
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs DYAI
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs DYAI
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs DYAI
argenx SE ARGX $971.55 $908.40 −7% vs DYAI
CSL Limited CSL A$201.68 A$181.40 −10% vs DYAI
Moderna, Inc MRNA $250.83 $158.70 −37% vs DYAI
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs DYAI
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs DYAI
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs DYAI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dyadic International Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dyadic International Inc Fair Value". https://www.fairvalue-calculator.com/stock/DYAI

Frequently asked questions

Is Dyadic International Inc (DYAI) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.2794 versus a price of $0.3700, about 24% lower (overvalued).
What is the fair value of DYAI?
Our estimate for Dyadic International Inc is $0.2794 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.3700.
What is the quality score of DYAI?
Dyadic International Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dyadic International Inc (DYAI)?
Our calculated price target is the estimate of $0.2794 (as of Nov 10, 2026). Cautious scenario $0.2096, optimistic scenario $0.3493. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Dyadic International Inc stock forecast for 2026?
Our estimate puts fair value at $0.2794, about 24% lower versus a price of $0.3700 (overvalued). Cautious scenario $0.2096, optimistic scenario $0.3493. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Dyadic International Inc (DYAI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dyadic International Inc it is $0.2794 per share (as of Nov 10, 2026), against a price of $0.3700.
Is Dyadic International Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, DYAI trades above its calculated fair value: price $0.3700, fair value $0.2794, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DYAI?
No. The price is what the market pays today ($0.3700); the fair value is what the company's own numbers justify ($0.2794). For Dyadic International Inc the two are $0.0906 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dyadic International Inc worth?
The market values Dyadic International Inc at about $13.5M (market capitalisation, as of Nov 10, 2026). Per share that is $0.3700; our models calculate a fair value of $0.2794 per share.
What do the bullish and bearish scenarios say about DYAI?
Our models span a range for Dyadic International Inc: cautious scenario $0.2096, base $0.2794, optimistic $0.3493 per share (as of Nov 10, 2026, price $0.3700). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dyadic International Inc (DYAI)?
Balance-sheet figures for Dyadic International Inc (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is DYAI from its 52-week high?
Dyadic International Inc trades at $0.3700, about 75% below its 52-week high of $1.47 and 9% above the low of $0.3400 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2794 is for.
Which stocks are comparable to Dyadic International Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dyadic International Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.3700, calculated fair value $0.2794 (−24%), Quality Score 22/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Dyadic International Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dyadic International Inc (DYAI)?
The closing price on Nov 10, 2026 was $0.3700. Our estimate is $0.2794, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dyadic International Inc right now?
The price sits above even our optimistic bull case ($0.3493). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Dyadic International Inc

How large is the market capitalisation of Dyadic International Inc (DYAI)?
The market capitalisation of Dyadic International Inc is $13.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dyadic International Inc (DYAI)?
The price-to-sales ratio of Dyadic International Inc is 3.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dyadic International Inc (DYAI)?
Earnings per share at Dyadic International Inc are $−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Dyadic International Inc (DYAI)?
The return on equity (ROE) of Dyadic International Inc is −2,827% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dyadic International Inc (DYAI)?
On an EBIT basis the return on assets of Dyadic International Inc is −74.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dyadic International Inc (DYAI)?
The operating margin of Dyadic International Inc is −213% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dyadic International Inc (DYAI)?
Revenue at Dyadic International Inc is growing −0.6% versus a year earlier (3y avg −25.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Dyadic International Inc (DYAI) generate?
The free cash flow of Dyadic International Inc is −$5.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Dyadic International Inc (DYAI) carry?
The net debt of Dyadic International Inc is $438K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Dyadic International Inc in the live analysis

One click puts Dyadic International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.